

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

JANSSEN BIOTECH, INC.,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. 22-1549-MN
	)	
AMGEN INC.,	)	
	)	
Defendant.	)	
	)	

**PLAINTIFF’S MOTION FOR A PRELIMINARY INJUNCTION**

Pursuant to Federal Rule of Civil Procedure 65, Plaintiff Janssen Biotech, Inc. (“Janssen”) hereby moves for a preliminary injunction enjoining Defendant Amgen, Inc. (“Amgen”) from manufacturing in commercial quantities, using in commercial quantities, offering to sell, selling within the United States, or importing for commercial purposes into the United States its ABP 654 biosimilar product.

The grounds for this motion are set forth in Plaintiff’s Memorandum in Support of its Motion For a Preliminary Injunction, the supporting declarations of Brian Smith, Dr. Matthew S. Croughan, John C. Jarosz, and Cecilia Sanabria, and exhibits attached thereto, filed contemporaneously herewith.

Date: March 6, 2023

Respectfully submitted,

MCCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

Alexandra M. Joyce (#6423)

Renaissance Centre

405 N. King St.

Wilmington, DE 19801

(302) 984-6300

dsilver@mccarter.com

ajoyce@mccarter.com

*Attorneys for Plaintiff  
Janssen Biotech, Inc.*

OF COUNSEL:

Michael A. Morin

David P. Frazier

Inge A. Osman

Cecilia Sanabria

LATHAM & WATKINS LLP

555 Eleventh Street, NW, Suite 1000

Washington, DC 20004c

(202) 637-2200

Michael Seringhaus

LATHAM & WATKINS LLP

140 Scott Drive

Menlo Park, CA 94025

(650) 328-4600

Gabrielle LaHatte

LATHAM & WATKINS LLP

505 Montgomery Street, Suite 2000

San Francisco, CA 94111

(415) 491-0600

**RULE 7.1.1 CERTIFICATION**

Pursuant to D. Del. LR 7.1.1, counsel for Plaintiff Janssen Biotech, Inc. certifies that counsel for the parties, including Delaware counsel, discussed the subject matter of the foregoing motion and the relief sought, and that the parties have been unable to reach agreement.

*/s/ Daniel M. Silver*

\_\_\_\_\_  
Daniel M. Silver (#4758)